# Biagio Ricciuti

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/biagio-ricciuti/

## Facts

| Field | Value |
| --- | --- |
| Citations | 11,209 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 55 |
| i10-index | 134 |
| Last Known Institution | Dana-Farber Cancer Institute |
| OpenAlex ID | https://openalex.org/A5030450694 |
| ORCID iD | 0000-0002-0651-2678 |
| Works | 1,111 |

## Researcher papers

- [Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer](https://scholariq.org/papers/multisystem-immune-related-adverse-events-associated-with-immune-checkpoint/)
- [A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable](https://scholariq.org/papers/a-multicenter-study-of-body-mass-index-in-cancer-patients-treated-with-anti-pd-1/)
- [Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels](https://scholariq.org/papers/association-of-high-tumor-mutation-burden-in-non-small-cell-lung-cancers-with/)
- [Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status](https://scholariq.org/papers/diminished-efficacy-of-programmed-death-ligand-1-inhibition-in-stk11-and-keap1/)
- [Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis](https://scholariq.org/papers/impact-of-immune-related-adverse-events-on-survival-in-patients-with-advanced/)
- [Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression](https://scholariq.org/papers/outcomes-to-first-line-pembrolizumab-in-patients-with-non-small-cell-lung-cancer/)
- [Immune Checkpoint Inhibitor Outcomes for Patients With Non–Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications](https://scholariq.org/papers/immune-checkpoint-inhibitor-outcomes-for-patients-with-non-small-cell-lung/)
- [Optimizing the safety of antibody–drug conjugates for patients with solid tumours](https://scholariq.org/papers/optimizing-the-safety-of-antibody-drug-conjugates-for-patients-with-solid/)
- [Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC](https://scholariq.org/papers/molecular-mechanisms-of-acquired-resistance-to-met-tyrosine-kinase-inhibitors-in/)
- [Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study](https://scholariq.org/papers/clinical-outcomes-of-patients-with-advanced-cancer-and-pre-existing-autoimmune/)
- [Whole exome sequencing (WES) analysis of transformed small cell lung cancer (SCLC) from lung adenocarcinoma (LUAD)](https://scholariq.org/papers/whole-exome-sequencing-wes-analysis-of-transformed-small-cell-lung-cancer-sclc/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [RNA modifications and cancer](https://scholariq.org/topics/rna-modifications-and-cancer/)

## Researcher university

- [Dana-Farber Cancer Institute](https://scholariq.org/institutions/dana-farber-cancer-institute/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.